CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 2
Active (not recruiting)
NCT06537999

Claseprubart (DNTH103)

Sponsored by Dianthus Therapeutics ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
—
Est. Completion
—
Enrollment Target
36 participants
Status
Active (not recruiting)
Study Design
Primary Endpoint
Safety, tolerability, pharmacometrics, efficacy of DNTH103
Registry
ClinicalTrials.gov Record
Registry ID
NCT06537999
Direct Link
clinicaltrials.gov/NCT06537999 ↗
Related Treatment
Treatment Being Studied
Claseprubart (DNTH103) →